Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828491 | 0.92 | TSHR (0.67) | NPC1RAB9ATSHRHPGDSMN1; SMN2 | |
| SCHEMBL18101284 | 0.87 | KDM4E (0.70) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL18101248 | 0.87 | KDM4E (0.70) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL18101240 | 0.87 | KDM4E (0.70) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL18101244 | 0.87 | KDM4E (0.70) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL144609 | 0.85 | ALDH1A1 (0.69) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL3064183 | 0.83 | ALDH1A1 (0.72) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL31207820 | 0.81 | TSHR (0.86) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL3735582 | 0.81 | KDM4E (0.77) | NPC1RAB9AALDH1A1TSHRKMT2A | |
| SCHEMBL5531108 | 0.81 | NPC1 (0.63) | NPC1RAB9AALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2061792-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1606251-B1 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | CHEMOCENTRYX INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| WO-2008033464-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| EP-1606251-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | ChemoCentryx Inc (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004058705-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | CHEMOCENTRYX (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | NPC1 66/4885RAB9A 1709/4885ALDH1A1 319/4885 |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | NPC1 65/4885RAB9A 4072/4885ALDH1A1 741/4885 |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | NPC1 1009/4885RAB9A 2534/4885ALDH1A1 910/4885 |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CCL2, CCR2, CXCR2 | NPC1 1009/4885RAB9A 2534/4885ALDH1A1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.